Arcturus Therapeutics Third Quarter 2026 Earnings Call - ARCTURUS THERAPEUTICS HOLDINGS INC

Financial Performance:

• Cash and cash equivalents stood at $184.8 million as of September 30, 2026, down $46.1 million year-to-date, primarily driven by clinical development costs.
• Revenue was $18.3 million for the quarter and $23.3 million for the nine-month period; the quarterly increase was driven by a $12 million termination payment and deferred revenue recognition from the CSL Sequrus collaboration, partially offset by lower grant revenue.
• Net loss narrowed to $7.4 million for the quarter (vs. $13.4 million prior year) and was $58.2 million for the nine months (vs. $36.7 million prior year).
• R&D expenses decreased to $17 million for the quarter and $56 million for the nine months, attributed to reduced clinical/manufacturing activities on lower-priority programs and lower personnel costs.
• General and administrative expenses remained stable at $10.5 million for the quarter and $30.9 million year-to-date.
• The company maintains a cash runway of over two years through year-end 2028.

Guidance and Future Outlook:

• Plans to initiate Phase 2 dosing for ARCT-2601 (OTC deficiency) in Q1 2027, with top-line data expected in the second half of 2027.
• Expect completion of ARCT-032 (Cystic Fibrosis) Phase 2 cohort 4 enrollment by year-end 2026; full cohort data presentation targeted for Q2 2027.
• CF go/no-go decision is expected upon top-line data availability, which will precede the full Q2 2027 data presentation.
• IND submission for the PKU program is planned for the second half of 2027.
• Commercialization objectives for the CoastAve COVID-19 vaccine in Europe/UK are targeted for 2027 following the transfer of marketing authorization.

Business Segments and Product Lines:

• Liver Therapeutics: ARCT-810 demonstrated meaningful biomarker activity in Phase 2 for OTC deficiency; ARCT-2601, the first candidate utilizing the new Lunar 2.0 platform, showed a 38-fold potency improvement in non-human primate models.
• Respiratory: ARCT-032 enrollment in Israel and Turkey is accelerating; all 20 subjects in cohort 4 will receive 10 mg doses.
• Vaccines: CoastAve commercialized in Japan for 2026-2027; Phase 1 pandemic influenza vaccine data published in Nature Communications showing single-dose potential.
• Technology & AI: Acquisition of MyNeo completed, adding AI-driven antigen design and neoantigen capabilities to support potential oncology collaborations and pipeline acceleration.
• Pipeline Expansion: Lunar 2.0 enabling expansion into PKU and gout therapies.

Market and Competitive Landscape:

• Arcturus focuses on Class 1 Cystic Fibrosis patients, a population where current standards of care are unavailable, positioning the firm as a first-mover.
• FDA engagement has been favorable; Type C meetings provided clarity on regulatory pathways for ARCT-2601.
• Competitor failures in the mRNA/LNP space (e.g., Vertex) attributed to safety issues and daily clinic administration requirements, which Arcturus aims to avoid through home administration and improved safety profile.
• Collaboration with Thermo Fisher Scientific remains strong; their decision to advance ARCT-032 to Phase 3 is triggered by top-line data, with Arcturus retaining control.

Risks and Challenges:

• Clinical development risks associated with translating the 38-fold potency gain from non-human primate models to human patients for ARCT-2601.
• Reliance on the upcoming Phase 2 data for ARCT-032 to trigger Phase 3 advancement and Thermo Fisher funding.
• Regulatory uncertainty regarding final Phase 3 endpoint definitions for OTC deficiency, though FDA feedback on ammonia and glutamine biomarkers is positive.
• Market risks for vaccine commercialization in the US (partnering required) and Europe, despite recent transfer of marketing authorization rights.

Management Commentary and Tone:

• Management tone is confident and disciplined, emphasizing "safe and effective delivery" as the core thesis.
• CEO Joe Payne highlighted the strategic value of the Lunar 2.0 platform and the MyNeo acquisition as key drivers for long-term value creation.
• CFO Denis Mulroy emphasized capital discipline, noting cost reductions from scaling back non-priority programs while maintaining a strong balance sheet.
• Leadership expressed high confidence in the 12-week study duration for CF to capture clinical signals and the ability to manage safety in open-label trials.

Analyst Questions and Answers:

• CF Timing: Top-line data for CF will be available before the full Q2 2027 presentation, informing the go/no-go decision, though specific timing for the decision is not fixed to year-end.
• OTC Dosing: ARCT-2601 will enroll up to 6 subjects to establish proof-of-concept; the goal is to present combined data with ARCT-810 at an FDA End-of-Phase 2 meeting.
• Safety Profile: Management confirmed no severe adverse events in the CF trial so far; unlike competitors, Arcturus does not require systemic steroids or daily clinic visits, allowing home administration.
• Oncology Strategy: While MyNeo adds neoantigen design capabilities, management clarified the primary focus remains on executing the therapeutic pipeline, with oncology viewed through a partnership lens.
• REACH Study: The CF Foundation's natural history study will likely serve as a control for Phase 3, potentially reducing patient enrollment needs; data expected late 2027.
• PKU Data: Preclinical data will be included in the upcoming IND filing and shared publicly as part of that process.

Other Key Points:

• The 38-fold potency increase in Lunar 2.0 technology is the primary differentiator for the next-generation OTC program.
• The company is prioritizing patients with higher baseline ammonia/glutamine levels in the ARCT-2601 trial to maximize measurable deltas.
• CoastAve marketing authorization rights have been transferred from CSL Sequrus to Arcturus for the EU and UK, enabling independent commercial evaluation.
• The pandemic influenza vaccine data supports the viability of self-amplifying mRNA for single-dose pandemic response.